The medical imaging firm reports Q2 2026 revenue of $3.9 million and reaffirms its full-year outlook while targeting a key regulatory submission.
Hyperfine Inc. maintained its 2026 revenue guidance of $20M-$22M after posting $3.9 million in Q2 2026 revenue, its second-highest quarterly total. The company highlighted continued execution across commercial and operational priorities during the period.
The $3.9 million revenue figure follows a prior quarter that also reflected strong performance, though specific comparisons were not detailed. Management reiterated confidence in meeting its annual targets while advancing product development.
Hyperfine aims to submit its contrast agent for FDA review by year-end 2026, a milestone that could expand its market opportunities if approved.